# Alí Duarte‐García

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/ali-duarte-garcia/

## Facts

| Field | Value |
| --- | --- |
| Citations | 4,548 |
| Field | Systemic Lupus Erythematosus Research |
| h-index | 34 |
| i10-index | 64 |
| Last Known Institution | Mayo Clinic |
| OpenAlex ID | https://openalex.org/A5025997714 |
| ORCID iD | 0000-0003-1749-5719 |
| Works | 151 |

## Researcher papers

- [The 2023 <scp>ACR</scp>/<scp>EULAR</scp> Antiphospholipid Syndrome Classification Criteria](https://scholariq.org/papers/the-2023-scp-acr-scp-scp-eular-scp-antiphospholipid-syndrome-classification/)
- [2023 ACR/EULAR antiphospholipid syndrome classification criteria](https://scholariq.org/papers/2023-acr-eular-antiphospholipid-syndrome-classification-criteria/)
- [The Epidemiology of Antiphospholipid Syndrome: A Population‐Based Study](https://scholariq.org/papers/the-epidemiology-of-antiphospholipid-syndrome-a-population-based-study/)
- [Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: Results from the COVID-19 Global Rheumatology Alliance physician registry](https://scholariq.org/papers/associations-of-baseline-use-of-biologic-or-targeted-synthetic-dmards-with-covid/)
- [A Rush to Judgment? Rapid Reporting and Dissemination of Results and Its Consequences Regarding the Use of Hydroxychloroquine for COVID-19](https://scholariq.org/papers/a-rush-to-judgment-rapid-reporting-and-dissemination-of-results-and-its/)
- [Epidemiology of Antiphospholipid Syndrome in the General Population](https://scholariq.org/papers/epidemiology-of-antiphospholipid-syndrome-in-the-general-population/)
- [<scp>SARS</scp>–<scp>CoV</scp>‐2 Infection and <scp>COVID</scp>‐19 Outcomes in Rheumatic Diseases: A Systematic Literature Review and Meta‐Analysis](https://scholariq.org/papers/scp-sars-scp-scp-cov-scp-2-infection-and-scp-covid-scp-19-outcomes-in-rheumatic/)
- [Antiphospholipid Syndrome](https://scholariq.org/papers/antiphospholipid-syndrome/)
- [16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends](https://scholariq.org/papers/16th-international-congress-on-antiphospholipid-antibodies-task-force-report-on/)
- [Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19](https://scholariq.org/papers/association-between-tumor-necrosis-factor-inhibitors-and-the-risk-of/)
- [Incidence, Prevalence, and Mortality of Lupus Nephritis: A <scp>Population‐Based</scp> Study Over Four Decades Using the Lupus Midwest Network](https://scholariq.org/papers/incidence-prevalence-and-mortality-of-lupus-nephritis-a-scp-population-based-scp/)

## Researcher topics

- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)
- [Rheumatoid Arthritis Research and Therapies](https://scholariq.org/topics/rheumatoid-arthritis-research-and-therapies/)
- [COVID-19 Clinical Research Studies](https://scholariq.org/topics/covid-19-clinical-research-studies/)
- [Spondyloarthritis Studies and Treatments](https://scholariq.org/topics/spondyloarthritis-studies-and-treatments/)
- [Systemic Sclerosis and Related Diseases](https://scholariq.org/topics/systemic-sclerosis-and-related-diseases/)

## Researcher university

- [Mayo Clinic](https://scholariq.org/institutions/mayo-clinic/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.